Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
This study has been completed.
Sponsor:
USC/Norris Comprehensive Cancer Center
Collaborator:
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Information provided by:
USC/Norris Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00183742
First received: September 9, 2005
Last updated: January 10, 2008
Last verified: January 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubicin (also called Doxil), when given together and to determine the side effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease the size of several different tumors. Taxotere is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for the treatment of ovarian cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Cancer Carcinoma |
Drug: liposomal doxorubicin and docetaxel |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) |
Resource links provided by NLM:
Further study details as provided by USC/Norris Comprehensive Cancer Center:
Primary Outcome Measures:
- To determine the maximum tolerated dose (MTD) of liposomal doxorubicin (Doxil) administered every 4 weeks or every 2 weeks in combination with docetaxel (Taxotere) administered on a weekly schedule
- To establish the toxicity profile of this combination
| Estimated Enrollment: | 35 |
| Study Start Date: | December 2000 |
| Study Completion Date: | May 2006 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histological proof of advanced or recurrent solid tumor which has failed prior therapy, or for which no effective therapy is available.
- Ovarian cancer patients (or primary peritoneal carcinoma) whose only manifestation of disease is an elevated cancer antigen (CA) 125 of > 100 are eligible.
- SWOG performance status 0-2.
- Absolute granulocyte count (AGC) greater than or equal to 1.5; platelets greater than or equal to 100,000.
- Total bilirubin less than or equal to the upper limit of normal (ULN).
- Transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional upper limit of normal (ULN) if alkaline phosphatase is <= ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are <= ULN. However, patients who have both transaminase elevation > 1.5 x ULN and alkaline phosphatase > 2.5 x ULN are not eligible for this study (due to decreased clearance of docetaxel and increased risk of toxicity).
- Age greater than or equal to 18 years.
- Fully recovered from acute toxicities from chemotherapy, radiation, or surgery.
- Negative serum pregnancy test, if patient is female, still fertile, and sexually active.
Exclusion Criteria:
- Prior treatment with Doxil or weekly docetaxel. Prior docetaxel administered every 3 weeks is allowed.
- Evidence of moderate peripheral neuropathy greater than or equal to grade 2.
- Medical, social, or psychological factors interfering with compliance.
- Known history of cardiac disease (congestive heart failure, coronary artery disease) that would preclude treatment with Doxil in the opinion of the investigator.
- Cardiac ejection fraction < 50%
- Pregnancy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00183742
Locations
| United States, California | |
| U.S.C./Norris Comprehensive Cancer Center | |
| Los Angeles, California, United States, 90033 | |
Sponsors and Collaborators
USC/Norris Comprehensive Cancer Center
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Investigators
| Principal Investigator: | Syma Iqbal, M.D. | U.S.C./Norris Comprehensive Cancer Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00183742 History of Changes |
| Other Study ID Numbers: | 0C-00-6 |
| Study First Received: | September 9, 2005 |
| Last Updated: | January 10, 2008 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by USC/Norris Comprehensive Cancer Center:
|
Phase 1 Phase I Phase one Solid tumor |
Additional relevant MeSH terms:
|
Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Doxorubicin |
Docetaxel Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013